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Premature adrenarche (PA), the early rise in adrenal androgen production leading to prepubertal 
signs of androgen action, has been connected with adverse metabolic features. The metabolic 
syndrome is characterized by low-grade inflammation which in turn is associated with increases 
in circulating proinflammatory cytokines, like tumor necrosis factor-alpha (TNF-α) and interleukin-6 
(IL-6). We tested the hypothesis that serum concentrations of TNF-α and IL-6 are increased in PA 
by studying 73 children with PA and 98 age- and gender-matched controls. Serum TNF-α and 
IL-6 concentrations were measured using a multiplex bead array. The subjects were genotyped 
for the TNF-α gene -308 G > A polymorphism (known to affect TNF-α gene transcription), and 
genotype–phenotype associations were studied. The mean serum TNF-α concentration was 
higher in the PA than control children (20.4 vs. 18.4 pg/ml, P = 0.048), whereas there was no 
significant difference in the mean serum IL-6 concentrations between the study groups. The 
difference in TNF-α was not explained by excess body weight in the PA subjects as the difference 
remained significant after BMI-adjustment (P = 0.038). In the PA group, TNF-α concentration 
was not associated with metabolic-endocrine features, but high IL-6 was associated with lower 
birth weight. There was no difference in the genotype distribution of the TNF-α gene -308 G > A 
polymorphism between the PA and control groups. In conclusion, PA was associated with 
increased serum TNF-α concentrations which, unexpectedly, were not connected with BMI or 
insulin resistance. The TNF-α gene -308 G > A polymorphism does not seem to be associated 
with the development of PA.
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in the metabolic syndrome (Alberti et al., 2006; Despres and 
Lemieux, 2006), and both IL-6 and TNF-α expression is higher in 
visceral than subcutaneous fat (Fried et al., 1998; Cao et al., 2008). 
Interestingly, excess central fat mass has been observed also in girls 
with PA (Ibanez et al., 2003).
High circulating TNF-α and IL-6 concentrations are associ-
ated with obesity and insulin resistance. Increased TNF-α serum 
concentrations have been observed in type 2 diabetes mellitus 
(Katsuki et al., 1998), in obese subjects (Dandona et al., 1998), 
and in normal-weight polycystic ovary syndrome (PCOS) patients 
(Gonzalez et al., 1999). High circulating IL-6 concentrations have 
also been connected with components of the metabolic syn-
drome, especially with insulin resistance (Fernandez-Real et al., 
2001; Bastard et al., 2002). A recent study found that the connec-
tion between obesity and proinflammatory markers exists already 
before puberty (Mauras et al., 2010). As regards to the mechanisms, 
TNF-α can directly interfere with insulin signaling (Hotamisligil 
et al., 1993, 1996), and IL-6 produced from central fat may directly 
increase hepatic secretion of triglycerides, as has been shown in rats 
(Nonogaki et al., 1995).
IntroductIon
Premature adrenarche (PA) refers to the clinical condition in which 
earlier than normal increase in the production of adrenal androgens 
leads to clinical signs of androgen action before the age of 8 years 
in a girl or 9 years in a boy, and androgen producing tumors, con-
genital adrenal hyperplasia, and precocious puberty are excluded 
(Voutilainen et al., 1983; Ibanez et al., 2000; Utriainen et al., 2009a). PA 
has been connected with overweight and features of the metabolic and 
polycystic ovary syndromes (Ibanez et al., 1993, 1998a; Oppenheimer 
et al., 1995; Utriainen et al., 2007). The origins of PA remain to be 
elucidated, but the pathogenesis is apparently multifactorial.
Low-grade inflammation is generally accepted to be involved in 
the pathogenetic process of the metabolic syndrome and cardio-
vascular diseases (reviewed in Antuna-Puente et al., 2008; Rizvi, 
2009). This connection may be caused by increased number of 
macrophages in the adipose tissue (Weisberg et al., 2003). In obesity, 
adipose tissue macrophages are characterized by overproduction 
of proinflammatory cytokines, like tumor necrosis factor-alpha 
(TNF-α) and interleukin 6 (IL-6) (Antuna-Puente et al., 2008). 
Increased accumulation of central fat is considered a key  element 
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gestational age (Pihkala et al., 1989), and ponderal  indices were 
calculated with the formula: BW(g)/BL(cm)3 × 100 as previously 
described (Utriainen et al., 2009b). Current height and weight 
were measured, body mass index (BMI; kg/m2) was calculated 
and converted to BMI SD scores according to British reference 
values (Cole et al., 1995) as described (Utriainen et al., 2009b). 
Blood pressure was measured with a standard sphygmoma-
nometer from the left arm after 30-min rest in supine position 
and recorded as the average of three repeated measurements 
(Utriainen et al., 2007).
Blood samplIng and BIochemIcal analyses
Venous blood samples for biochemical analyses and DNA isolation 
were drawn between 0900 and 1000 h after an overnight fast. All 
serum samples were separated within an hour of sampling, imme-
diately frozen and stored at −80°C until assayed. A standard 2-h 
oral glucose tolerance test (OGTT) and ACTH-test (1 μg/1.73 m2 
Synacthen®, Novartis Pharma GmbH, Nürnberg, Germany) were 
performed as described (Utriainen et al., 2007, 2009a). The meth-
ods for steroid, glucose, sex hormone binding globulin (SHBG), 
and insulin measurements have also been previously described 
(Utriainen et al., 2007, 2009a). TNF-α and IL-6 concentrations 
were measured using Bio-Plex® Pro Human Diabetes Panel with 
premixed multiplex beads (Bio-Rad Laboratories, Hercules, CA, 
USA). The Bio-Plex cytokine assay is based on flow cytometry and 
fluorescence detection. It is designed for multiplexed quantitative 
measurement of several cytokines in a single well using as little as 
50 μl of sample.
genotypIng
DNA samples were available for 73 PA and 97 control subjects. DNA 
was isolated from whole blood samples using the Wizard Genomic 
DNA Purification Kit (Promega, Madison, WI, USA). The sam-
ples were genotyped for the TNF-α -308 G > A (rs1800629) poly-
morphism using TaqMan Allelic Discrimination Assays (Applied 
Biosystems, Foster City, CA, USA). The TaqMan genotyping reac-
tion was performed on a GeneAmp PCR system 2700 (50°C for 
2 min, 95°C for 10 min, followed by 40 cycles of 95°C 15 s, and 
60°C 1 min) and fluorescence was detected using an ABI Prism 7000 
sequence detector (Applied Biosystems). The primer sequences are 
available from the authors by request.
statIstIcal analyses
Because of the small number of subjects homozygous for the 
TNF-α -308 A allele, the genotypes G/A and A/A were combined for 
analyses. The distribution of genotypes was analyzed with Pearson’s 
Chi-square test. The difference in sex distribution between the gen-
otype groups was analyzed with Fischer’s exact test. All continuous 
parameters were tested for normality. Differences in the TNF-α 
and IL-6 concentrations between the PA and control groups were 
analyzed with independent samples t-test or Mann–Whitney U test 
in case of non-normal distribution. Mann–Whitney U test was 
used to compare the genotype groups among the PA children and 
between the TNF-α/IL-6 quartiles because of the small number 
of subjects in each subgroup. To compare differences between the 
study groups independently of confounding factors, univariate 
linear model was used.
Interestingly, one study group has reported that girls born 
 small-for-gestational age and presenting with premature pubarche 
(PP, the most prominent clinical sign of PA), had higher circulating 
neutrophil count than control girls (Ibanez et al., 2005). Another 
small study found higher serum TNF-α concentrations in PA than 
control subjects (Mathew et al., 2008). These findings suggest that 
inflammation may play a role in PA, which in turn associates with 
an increased risk of unfavorable metabolic features.
The expression of TNF-α in skeletal muscles and adipose tissue 
correlates with fat mass and insulinemia (Hotamisligil et al., 1995). 
Polymorphism G > A at position -308 in the promoter region of the 
TNF-α gene has been shown to increase transcriptional activity of 
the TNF-α gene in vitro (Kroeger et al., 1997; Wilson et al., 1997). 
This polymorphism has also been connected with insulin resist-
ance and obesity (Fernandez-Real et al., 1997). In addition to insu-
lin signaling pathways, TNF-α may be connected with androgen 
metabolism. In a Spanish study, lean hyperandrogenic women had 
slightly higher serum TNF-α concentrations than the lean controls, 
and the carriers of the TNF-α -308 A variant had higher androgen 
concentrations than those with the -308 G allele only in the whole 
study population (Escobar-Morreale et al., 2001).
On the basis of the observed connections between inflamma-
tion, metabolic syndrome, and hyperandrogenism, we tested the 
hypothesis that TNF-α and IL-6 concentrations are increased in 
PA. We also examined whether TNF-α polymorphism associates 
with PA or TNF-α concentrations in children with PA.
materIals and methods
suBjects
The PA group comprised 73 children (63 girls) with any clinical 
sign(s) of adrenarche (pubic/axillary hair, acne, comedones, adult 
type body odor, or oily hair) before the age of 8 years in girls and 
9 years in boys. The age at examination had to be less than 9 years 
in girls and 10 years in boys. All children meeting the clinical criteria 
between October 2004 and January 2006 in our university hospital 
district were invited to participate in the Premature Adrenarche 
study. The control group comprised 98 healthy prepubertal children 
(18 boys) without any signs of androgen action. The recruitment 
and exclusion criteria of the subjects has been described previ-
ously in more detail (Utriainen et al., 2009a). Central puberty was 
excluded by Tanner staging (B1 or G1 in all subjects) and a GnRH 
test. Adrenal virilizing tumors and congenital adrenal hyperplasia 
were excluded by abdominal ultrasonography (performed for those 
with pubic or axillary hair) and an intravenous ACTH-test with 
17-OH-progesterone measurements. A serum sample for TNF-α 
and IL-6 measurements was available from 69 PA subjects and 95 
controls. The study protocol was approved by the Research Ethics 
Committee of the Kuopio University Hospital. An informed writ-
ten consent was obtained from the parents and an approval from 
the children themselves.
clInIcal assessment
The time of appearance of adrenarcheal signs was obtained by 
interviewing the parents and the subjects (Utriainen et al., 2009a). 
Birth measures were obtained from hospital and well baby clinic 
records. Birth weight (BW) and length (BL) were converted to SD 
scores by plotting them on the growth charts according to sex and 
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tnF-α -308 g > a genotype
There was no difference in the genotype distribution of the TNF-α 
gene -308 G > A polymorphism between the PA and control groups 
(Table 2). The same was true when the children with both  clinically 
Hardy–Weinberg equilibrium and minor allele frequency (MAF) 
were calculated according to standard procedures using Chi-Square 
test. All analyses were performed with SPSS 16.0 statistical package 
(SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically 
significant in all analyses. Values are presented as mean ± 95% con-
fidence interval unless otherwise mentioned.
results
serum tnF-α and Il-6 concentratIons
Serum TNF-α concentrations were significantly higher in the PA 
than control children (Table 1). Instead, the mean serum IL-6 
concentration did not differ between the groups. Serum TNF-α 
and IL-6 concentrations were interconnected in both groups 
(r = 0.90, P < 0.001 and r = 0.75, P < 0.001 in the PA and control 
group, respectively). The difference in the TNF-α concentrations 
between the study groups remained significant when adjusted 
for BMI SDS (P = 0.038). There was no significant difference in 
the TNF-α levels between the PA children with pubic or axillary 
hair (n = 33) and those without sexual hair (n = 36) (19.7 vs. 
21.1 pg/ml, P = 0.48).
In the PA group, both TNF-α and IL-6 concentrations were 
inversely correlated with ponderal index at birth (r = −0.29, P = 0.017, 
and r = −0.40, P = 0.001, respectively) and with BW in kilograms 
(r = −0.36, P = 0.003, and r = −0.38, P = 0.001). There was also a 
trend toward higher TNF-α and IL-6 concentrations with lower 
BW SDS, but these correlations did not reach statistical significance 
(P = 0.11 and P = 0.07, respectively). None of these correlations was 
found in the control group. In both PA and control groups, serum 
TNF-α concentrations were positively correlated with OGTT mean 
glucose (r = 0.27, P = 0.03, and r = 0.23, P = 0.03, respectively). In 
the control group, TNF-α concentrations were also correlated with 
fasting glucose concentrations (r = 0.23, P = 0.024). In the PA group, 
serum TNF-α concentrations were inversely correlated with fasting 
serum insulin concentrations (r = −0.28, P = 0.02).
Serum TNF-α concentration was correlated with DHEAS only 
in the PA group (r = 0.35, P = 0.003). Serum IL-6 concentration was 
also positively correlated with serum DHEAS and DHEA concentra-
tions in the PA (r = 0.45, P < 0.001, and 0.24, P = 0.04, respectively), 
but not in the control group (P > 0.1 for both). Neither TNF-α nor 
IL-6 concentration was correlated with age, BMI SDS, fat percent-
age, SHBG or lipid concentrations, insulin sensitivity (ISI
comp
) or 
HOMA-IR indices in either study group (P > 0.05 for all).
When all the study subjects were pooled and divided into 4 sub-
groups according to the TNF-α concentrations, altogether 63% of 
the PA subjects were categorized into the highest two quartiles with 
only 19% in the lowest one, whereas 60% of the controls were in the 
lowest two quartiles (P = 0.027 for the distribution by Chi-Square 
test). When the PA group was further divided into four subgroups 
based on the IL-6 concentrations, the subjects in the highest quartile 
had lower BW and BW SDS (3050 vs. 3490 g, P = 0.03 and −0.62 
vs. + 0.10 SD, P = 0.007), and higher DHEAS concentrations (2.8 
vs. 1.9 μmol/l, P = 0.03) than those in the lowest quartile. There 
were no differences in the other metabolic features across the IL-6 
quartiles. When the PA subjects were similarly divided according to 
the TNF-α concentrations, there were no significant differences in 
the metabolic-endocrine features between the subjects with their 
TNF-α concentrations in the highest vs. the other quartiles.
Table 1 | Biochemical and anthropometric characteristics of children 
with signs of premature adrenarche and those of prepubertal control 
children.
Current 
measurements,   
mean (95% CI)
PA (n = 69) Control (n = 95) P value
Serum TNF-alpha  
(pg/ml)
20.4 (18.5–22.3) 18.4 (17.3–19.5) 0.048
Serum IL-6 (pg/ml) 9.5 (8.3–10.7) 8.9 (8.2–9.6) 0.35
Characteristics*, 
mean ± SD
PA (n = 69) Control (n = 95) P value
Age (years) 7.45 ± 0.9 7.49 ± 0.9 0.78
BMI SDS 1.0 ± 1.2 0.41 ± 1.2 0.004#
Fat percent (%) 22.3 ± 9.3 18.1 ± 9.3 0.004#
Birth weight (g) 3390 ± 670 3610 ± 590 0.02
Birth weight SDS −0.07 ± 1.1 0.19 ± 1.0 0.12
Ponderal index 2.8 ± 0.2 2.8 ± 0.3 0.61
SBP (mmHg) 104 ± 10 100 ± 9.4 0.004
DBP (mmHg) 63 ± 8.8 61 ± 8.8 0.06
P-Glucose, fasting 
(mmol/l)
4.9 ± 0.3 4.8 ± 0.3 0.64
P-Glucose, mean 
OGTT (mmol/l)
6.1 ± 0.8 6.2 ± 0.9 0.79
S-Insulin, fasting (IU/l) 5.6 ± 2.5 4.5 ± 2.3 0.001#
S-Insulin, mean OGTT 
(IU/l)
36 ± 23 26 ± 11 <0.001#
HOMA-IR 1.3 ± 0.4 1.1 ± 0.5 <0.001#
S-TC (mmol/l) 4.3 ± 0.7 4.2 ± 0.7 0.67
S-HDL (mmol/l) 1.4 ± 0.3 1.5 ± 0.3 0.089#
S-LDL (mmol/l) 2.6 ± 0.6 2.5 ± 0.6 0.19
S-TG (mmol/l) 0.67 ± 0.30 0.60 ± 0.30 0.11#
S-SHBG (nmol/l) 83 ± 38 103 ± 29 <0.001#
S-DHEAS (μmol/l) 2.1 ± 1.3 0.98 ± 0.7 <0.001#
S-DHEA (nmol/l) 8.0 ± 4.2 4.6 ± 2.3 <0.001#
S-∆4A (nmol/l) 2.7 ± 1.4 1.6 ± 0.9 <0.001#
S-17-OHP (nmol/l); 
median (range)




0.41 (<0.35–1.17) 0.35 (<0.35–1.37) 0.02#
S-Cortisol (nmol/l) 256 ± 121 244 ± 102 0.50
*Previously reported in part (Utriainen et al., 2007, 2009a,b).
SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; 
TG, triglycerides; DHEAS, dehydroepiandrosterone sulfate; ∆4A, androste-
nedione; 17-OHP, 17-hydroxyprogesterone
P values obtained from Independent samples t-test or #Mann–Whitney test 
(non-normal distribution).
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tive relationship between circulating TNF-α and the amount of 
 adipose tissue (Hotamisligil et al., 1995; Kern et al., 1995). A possible 
explanation for this discrepancy is that we could not correlate the 
TNF-α concentrations separately with visceral and subcutaneous 
fat. Increased amount of central fat may play a major role in the 
obesity-induced increase in TNF-α production. In a study by Cao 
et al. (2008), the expression of TNF-α was higher in visceral than 
subcutaneous fat tissue. It is also of note that children with PP and 
biochemically ascertained PA seem to have increased central fat 
even in normal-weight subjects (Ibanez et al., 2003).
It was also somewhat unexpected that TNF-α concentrations 
were not positively correlated with fasting or OGTT insulin con-
centrations in our study, although hyperinsulinism is the metabolic 
abnormality that has clearly been associated with PA (Ibanez et al., 
1998a; Utriainen et al., 2007). It is possible that the association of 
TNF-α concentrations with obesity and insulin resistance is not so 
clear in childhood as it is in later life. This possibility was recently 
suggested by Andersen et al. (2010) who were unable to show an 
association between plasma TNF-α or IL-6 concentrations and 
low insulin sensitivity or clustering of cardiovascular disease risk 
factors in a cohort of 9-year-old children. Instead, they showed that 
inflammation (C-reactive protein level) associated with fitness, fat-
ness, and cardiovascular disease risk score. The authors speculated 
that, in children, the influence of fatness and low fitness levels on 
insulin resistance and metabolic syndrome precedes any effects 
of cytokines (Andersen et al., 2010). Follow-up of PA and other 
study cohorts will hopefully show whether circulating TNF-α level 
in childhood could be helpful in identifying subjects in increased 
risk of developing adverse metabolic features and cardiovascular 
disease in adulthood.
The polymorphic site at -308 in the promoter region of the 
TNF-α gene could be considered a candidate gene locus for PA, 
because PA has been connected with overweight and features of the 
metabolic syndrome which both have been linked with increased 
adipose tissue inflammation and elevated TNF-α concentrations. 
Based on the findings of this study, the TNF-α -308 G > A poly-
morphism does not seem to have a role in the polygenic patho-
genesis of PA. Although those PA subjects carrying the A allele had 
statistically higher serum total and LDL cholesterol concentrations 
and lower diastolic BP than those with the more common G/G 
genotype, it is unlikely that these findings have clinical significance, 
because the lipid concentrations were opposite among the con-
trols and previous studies in adults have not shown an association 
between the TNF-α -308 G > A polymorphism and lipid levels.
Interestingly, IL-6 concentrations were inversely correlated 
with absolute BW in our PA children. Moreover, the PA subjects 
with the IL-6 concentration in the highest quartile had lower BW 
SDS than the other PA subjects. These findings are interesting in 
the light of the previously reported connections between BW and 
PP. With their Spanish girl population, Ibanez et al. (1998b) have 
shown that PP (caused by PA) is associated with low birth weight 
(LBW). More importantly, the same authors have connected LBW 
with subsequent development of hyperinsulinism and functional 
ovarian hyperandrogenism in PP girls. On the other hand, studies 
in other populations have not shown an association between LBW 
and PA (Utriainen et al., 2009b; Paterson et al., 2010).
and biochemically confirmed PA (serum DHEAS > 1 μmol/l; 
n = 64) were compared with the controls with biochemically 
excluded adrenarche (serum DHEAS < 1 μmol/l; n = 62) (geno-
type G/G-G/A-A/A distribution 80–18–2% and 72–27–2%, respec-
tively, P = 0.52). MAF did not differ between the children with PA 
and controls either (13 vs. 14%, P = 0.80). The distribution of the 
TNF-α -308 G > A polymorphism in the PA and control group 
was consistent with Hardy-Weinberg equilibrium (P = 0.63 and 
P = 0.27, respectively).
The mean serum TNF-α concentrations did not differ between 
the genotype subgroups in either the PA or control group (Table 3). 
In the PA group, those carrying the A allele had higher serum total 
and LDL cholesterol concentrations but lower diastolic BP than 
those with the G/G genotype. Instead, the controls with the A allele 
had lower total and LDL cholesterol level than those with the most 
common G/G genotype. The TNF-α genotype was not associated 
with fasting or OGTT glucose or insulin concentrations in either 
study group (Table 3).
dIscussIon
This study revealed that children with clinical signs of PA have 
higher circulating TNF-α concentrations but no difference in IL-6 
levels compared with healthy controls. There was no difference in 
the genotype distribution of the TNF-α -308 G > A polymorphism 
between the PA and control groups.
Increased serum levels of TNF-α can be considered as a marker 
of inflammation thought to play a significant role in the develop-
ment of insulin resistance, metabolic syndrome and cardiovascu-
lar diseases (Antuna-Puente et al., 2008; Rizvi, 2009). Moreover, 
TNF-α has been suggested to be a mediator of obesity-related 
insulin resistance and directly involved in the insulin receptor 
signaling (Hotamisligil et al., 1993, 1996). PA has been connected 
with several unfavorable metabolic characteristics at prepuber-
tal age (Oppenheimer et al., 1995; Ibanez et al., 1998a,b, 2009; 
Utriainen et al., 2007). The present finding of increased circulat-
ing TNF-α concentrations in our PA subjects is in line with these 
associations as is the recent study of Mathew et al. (2008) also 
reporting increased TNF-α concentrations in a small group of 
PA children.
Tumor necrosis factor-α concentrations were not correlated 
with BMI SDS or fat percentage in our prepubertal PA subjects. 
In contrast, most previous studies in adults have shown a posi-
Table 2 | Genotype frequencies of the TNF-alpha -308 polymorphism in 
children with signs of premature adrenarche (PA) and in control children.
TNF-alpha -308 
genotype
G/G G/A A/A Pa
Controls 74 (76%) 20 (21%) 3 (3%) 0.58; PA vs. 
control group
PA 53 (73%) 19 (26%) 1 (1.4%)
PP-PA 28 (80%) 7 (20%) 0 (0%)
Non-PP-PA 25 (66%) 12 (32%) 1 (3%) 0.17; PP-PA vs. 
non-PP-PA group
aG/G vs. G/A and A/A, Chi-square test. PP, premature pubarche.
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subjects with and without pubic or axillary hair in our study. A 
limitation of our study is the relatively small number of study sub-
jects for analyzing the genotype distributions. With this number 
of subjects, we cannot definitely rule out a minor contribution 
of the TNF-α -308 G > A polymorphism in the development 
of PA.
To conclude, children with PA had increased circulating TNF-α 
concentrations, which could indicate an increased risk of develop-
ing metabolic disturbances in later life. Genetic variation of the 
TNF-α -308 polymorphism does not seem to be involved in the 
pathogenetic process of PA. The observed association of higher 
circulating IL-6 with lower birth weight needs to be confirmed in 
other studies.
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The strength of this study is the representative  community-based 
cohort of children with PA and a well-matched control group from 
the same district. Within our hospital district, we consecutively 
recruited all children presenting with signs of PA to our Premature 
Adrenarche- study project. Moreover, as many as 73 of the 76 
eligible PA subjects participated in the study. The control subjects 
were identified through Finnish population register by random 
sampling based on age and gender. Thus, the control cohort can 
be considered a representative sample of healthy prepubertal chil-
dren in our district. As all the control subjects were originally 
recruited to the same Premature Adrenarche project as the PA 
children, all subjects were studied with the same study protocol 
and all samples were handled similarly. In our study, all subjects 
with clinical signs of PA where included. As reported, only about 
half of the subjects had pubarche and some had normal prepuber-
tal circulating androgen concentrations (Utriainen et al., 2009a). 
Thus, the comparison with other studies with more selected PA 
populations may be limited. However, there were no significant 
differences in the IL-6 or TNF-α concentrations between the PA 
Table 3 | Clinical and biochemical characteristics according to the TNF-α -308 G > A genotype groups among the subjects with premature 
adrenarche and controls.
Premature adrenarche Control
G/G (n = 53) G/A and A/A (n = 20) P a G/G (n = 74) G/A and A/A (n = 23) P a
Girls/boys (n) 44/9 19/1 0.3b 60/14 19/4 1.0b
Age 7.5 (7.2–7.7) 7.4 (6.9–7.9) 0.7 7.5 (7.2–7.7) 7.6 (7.3–7.9) 0.5
BMI SDS 1.17 (0.8–1.5) 0.60 (0.03–1.2) 0.07 0.43 (0.17–0.63) 0.30 (−0.27 to 0.89) 0.5
Birth weight SDS −0.02 (−0.4 to 0.3) −0.06 (−0.6 to 0.4) 1.0 0.15 (−0.08 to 0.39) 0.23 (−0.23 to 0.70) 0.6
Ponderal index at birth 2.8 (2.7–2.8) 2.8 (2.7–2.8) 0.6 2.8 (2.7–2.9) 2.8 (2.6–2.9) 0.5
SBP (mmHg) 105 (103–108) 102 (99–105) 0.1 100 (98–102) 101 (97–105) 0.6
DBP (mmHg) 65 (62–67) 60 (57–63) 0.04 61 (58–63) 61 (58–64) 0.5
TNF-alpha (pg/ml) (n = 69/95) 20.4 (18–23) 20.4 (18–23) 0.4 18.3 (17.0–19.5) 18.8 (16.5–21.2) 0.4
IL-6 (pg/ml) (n = 69/95) 9.5 (8.0–11) 9.3 (7.7–11) 0.9 8.8 (8.0–9.7) 9.2 (8.0–10.4) 0.2
Fasting P-glucose (mmol/l) 4.9 (4.8–5.0) 4.8 (4.7–4.9) 0.2 4.9 (4.8–4.9) 4.8 (4.7–5.0) 0.4
P-glucose, mean OGTT 6.2 (5.9–6.4) 6.1 (5.8–6.4) 0.9 6.2 (6.0–6.3) 6.2 (5.8–6.6) 0.8
S-insulin, baseline (IU/l) 5.8 (5.1–6.5) 5.4 (4.4–6.3) 0.7 4.5 (4.0–5.0) 4.6 (3.3–5.9) 0.9
S-Insulin, mean OGTT 39 (32–46) 32 (26–32) 0.2 26 (23–29) 30 (24–36) 0.2
S-TC (mmol/l) 4.2 (4.0–4.3) 4.5 (4.2–4.8) 0.05 4.3 (4.2–4.5) 3.9 (3.6–4.2) 0.02
S-HDL (mmol/l) 1.37 (1.3–1.5) 1.46 (1.3–1.6) 0.4 1.5 (1.4–1.6) 1.4 (1.3–1.6) 0.3
S-LDL (mmol/l) 2.5 (2.3–2.6) 2.8 (2.5–3.1) 0.02 2.6 (2.4–2.7) 2.2 (2.0–2.4) 0.03
S-TG (mmol/l) 0.66 (0.59–0.74) 0.72 (0.54–0.90) 1.0 0.63 (0.56–0.71) 0.55 (0.48–0.61) 0.4
S-DHEAS (μmol/l) 2.2 (1.8–2.6) 1.8 (1.4–2.2) 0.5 0.92 (0.78–1.1) 1.21 (0.81–1.6) 0.1
S-DHEA (nmol/l) 8.2 (7.0–9.4) 7.3 (5.8–8.8) 0.5 4.7 (4.1–5.3) 4.4 (3.5–5.4) 0.7
S-∆4A (nmol/l) 2.9 (2.5–3.2) 2.5 (1.8–3.2) 0.2 1.5 (1.3–1.7) 1.7 (1.3–2.1) 0.3
S-SHBG (nmol/l) 79 (69–89) 89 (68–109) 0.5 103 (96–110) 98 (86–110) 0.6
S-Cortisol (nmol/l) 260 (225–294) 257 (199–315) 0.9 252 (227–277) 220 (190–249) 0.2
Means (95% confidence intervals) are shown. aMann–Whitney U test if not otherwise stated. bFischer’s exact test.
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